Zobrazeno 1 - 10
of 175
pro vyhledávání: '"Ariel Miller"'
Autor:
Ariel Miller, Ellie Mews, Sophie Boisjolie-Gair, Dalton Smedley, HaeLee Ahn, Rebecca Haugen, Nicole Larson, Dane Rasmussen, Xiaobai Patrinostro, David Hermanson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7d3cb3bbeb454efb9ba0830ef3b95d1b
Publikováno v:
BMC Neurology, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Though adherence to disease-modifying therapies (DMTs) among persons with multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on adherence examined predictors beyond demographic and clinical chara
Externí odkaz:
https://doaj.org/article/2eda69aa6a7a4215ad2905c3a3b06c43
Autor:
Ron Milo, Elsebeth Staun-Ram, Dimitrios Karussis, Arnon Karni, Mark A. Hellmann, Erez Bar-Haim, Ariel Miller, The Israeli Neuroimmunology Study Group on COVID-19 Vaccination in Multiple Sclerosis, Lea Glass-Marmor, Anat Volkovitz, Sara Dishon, Zeev Dishon, Netta Kugelman, Zeev Nitsan, Marwan Alkrenawi, Nurit Hovel, Nir Michal, Vered Loew-Shavit, Lital Mizrahi, Marsel Zafrani, Panayiota Petrou, Nour Eddine-Yaghmour, Ariel Ginzberg, Ibrahim Kassis, Michelle Halimi, Keren Regev, Hadar Kolb, Ifat Vigiser, Yoav Piora, Irina Komarov, Avigail Hindi, Adi Wilf-Yarkoni, Itay Lotan, Elia Uri, Shaher Rotem, Hila Cohen
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundImmunomodulatory/immunosuppressive activity of multiple sclerosis (MS) disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 exposure or vaccination in patients with MS (PwMS). We evaluated the effect of DMTs on hum
Externí odkaz:
https://doaj.org/article/99fc8f24cbe5455180875aff2b241c01
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0250647 (2021)
BackgroundThe applicability of mobile digital technology to promote clinical care of people with multiple sclerosis (pwMS) is gaining increased interest as part of the implementation of patient-centered approaches. We aimed at assessing adherence to
Externí odkaz:
https://doaj.org/article/41d030923277486caa4f2c2384e9652b
Autor:
Efrat Neter, Ariel Miller
Publikováno v:
International Journal of MS Care.
Objectives: Up to 50% of individuals with multiple sclerosis (MS) who are prescribed disease-modifying treatments (DMTs) do not take them as advised. Although many studies report on DMT adherence rate, few studies report on interventions involving in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eee4e785c87a3f75c260af00a01dfbff
https://doi.org/10.7224/1537-2073.2022-018
https://doi.org/10.7224/1537-2073.2022-018
Autor:
Bridget Parsh, Ariel Miller
Publikováno v:
Nursing. 50:56-60
Venomous snakebites are surprisingly common in the US. This article provides an overview of what to do when a patient has been bitten by a North American pit viper, a venomous subset of indigenous snakes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445a63d6c6c663d4b7b13298b2743598
https://doi.org/10.1097/01.nurse.0000651632.09894.b4
https://doi.org/10.1097/01.nurse.0000651632.09894.b4
Publikováno v:
Multiple Sclerosis and Related Disorders. 68:104224
Though habitual behavior is part of medication-taking behavior, studies of adherence to medication among persons with relapsing remitting multiple sclerosis (PwRRMS) have not prospectively examined habit in relation to disease-modifying treatments (D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bef69572168d835b4ccd488f8968c0
https://doi.org/10.1016/j.msard.2022.104224
https://doi.org/10.1016/j.msard.2022.104224
The complex probabilistic properties of specific events determine the number or range of possible outcomes they can produce (i.e., outcome entropy). Do humans use estimates of outcome entropy for real-world events to reason about what is possible? We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4a42741e65b0eb5913ed44670b69aa1
https://doi.org/10.31234/osf.io/ay6hp
https://doi.org/10.31234/osf.io/ay6hp
Publikováno v:
Multiple Sclerosis and Related Disorders. 34:29-37
Background Fingolimod, an oral therapy for patients with relapsing Multiple Sclerosis (MS), traps C C chemokine receptor type 7 (CCR7)-expresssing lymphocytes within lymphoid tissues in the periphery, thereby supposedly reducing the infiltration of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7737578db3349b84ae083ef71e0453
https://doi.org/10.1016/j.msard.2019.06.016
https://doi.org/10.1016/j.msard.2019.06.016
Autor:
Rana Khsheibun, Tamar Paperna, Anat Volkowich, Izabella Lejbkowicz, Nili Avidan, Ariel Miller
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e102331 (2014)
The effects of interferon-beta (IFN-β), one of the key immunotherapies used in multiple sclerosis (MS), on peripheral blood leukocytes and T cells have been extensively studied. B cells are a less abundant leukocyte type, and accordingly less is kno
Externí odkaz:
https://doaj.org/article/51da5319c1cd46cbbd058a2e0aec2dd2